IHC 2021 | CGRP mAbs have changed migraine treatment approaches

Simona Sacco, MD, University of L’Aquila, L’Aquila, Italy, discusses how CGRP monoclonal antibodies (mAbs) have changed the landscape of migraine prevention. Prof. Sacco highlights that before the use of CGRP mAbs, several patients who were considered refractory to treatment now have an excellent response to CGRP mAbs. However, as expected, not all patients respond to the CGRP mAbs and continue to be defined as refractory according to the definition established by the European Headache Federation (EHF) consensus. This interview took place during the International Headache Congress 2021.